Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes (EXPLORE)

This study has been completed.
Sponsor:
Information provided by:
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01192425
First received: August 30, 2010
Last updated: August 31, 2010
Last verified: August 2010
  Purpose

Examine red and white blood cells of PNH patients with bone marrow failure syndromes.


Condition
Hemoglobinuria

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes

Resource links provided by NLM:


Further study details as provided by Alexion Pharmaceuticals:

Enrollment: 5580
  Eligibility

Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients at least 10 years of age with aplastic anemia, myelodyplastic syndromes or other bone marrow failure syndromes.

Criteria

Inclusion Criteria:

  • At least 10 years of age.
  • Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes

Exclusion Criteria:

  • Has any condition that might interfere with the patient's participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Michael Bombara, Senior Director, Global Clinical Operations, Alexion Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01192425     History of Changes
Other Study ID Numbers: P06-001
Study First Received: August 30, 2010
Last Updated: August 31, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Alexion Pharmaceuticals:
PNH clone cells
Aplastic Anemia
AA
Myelodysplastic Syndromes
MDS
bone marrow failure syndromes
FLAER
Paroxysmal Nocturnal Hemoglobinuria

Additional relevant MeSH terms:
Hemoglobinuria
Hemoglobinuria, Paroxysmal
Pancytopenia
Syndrome
Anemia
Anemia, Hemolytic
Bone Marrow Diseases
Disease
Hematologic Diseases
Myelodysplastic Syndromes
Pathologic Processes
Proteinuria
Signs and Symptoms
Urination Disorders
Urologic Diseases
Urological Manifestations

ClinicalTrials.gov processed this record on November 19, 2014